Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;9(6):587-591.
doi: 10.3892/mco.2018.1742. Epub 2018 Oct 5.

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases

Tomonari Suetsugu  1 , Nobuhisa Matsuhashi  1 , Takao Takahashi  1 , Toshiyuki Tanahashi  1 , Satoshi Matsui  1 , Hisashi Imai  1 , Yoshihiro Tanaka  1 , Kazuya Yamaguchi  1 , Kazuhiro Yoshida  1
Affiliations

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases

Tomonari Suetsugu et al. Mol Clin Oncol. 2018 Dec.

Abstract

Pathological complete response is achievable with mFOLFOX6 plus cetuximab therapy for unresectable colorectal cancer with multiple paraaortic lymph node metastases (mCRC) despite right-sided colonic origin. A 62-year-old woman with synchronous paraaortic lymph node metastases of transverse colon cancer was treated with mFOLFOX6 plus cetuximab as first-line therapy. The tumor size was markedly decreased following 6 courses of chemotherapy, and all lymph node metastases had disappeared. The patient then underwent conventional right hemicolectomy with D3 lymph node dissection plus sampling excision of the paraaortic lymph nodes. The pathological diagnosis was a complete response. The patient is currently alive 5 years after surgery with no signs of recurrence. The present study reported the apparent effectiveness of conversion therapy (surgery) with combination treatment with mFOLFOX6 plus cetuximab and radical surgery. We hypothesized that patients with different types of mCRC of right-sided colon origin may be effectively treated with anti-EGFR monoclonal antibodies.

Keywords: colon cancer; conversion surgery; neoadjuvant chemotherapy; pathological complete response.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Colonoscopy imaging shows hemicircular superficial elevated tumor. (B) CT colonography shows apple core sign in transverse colon as primary.
Figure 2.
Figure 2.
Positron emission tomography-computed tomography demonstrating primary lesion and multiple lymph node metastases.
Figure 3.
Figure 3.
(A) CT at first visit shows multiple paraaortic lymph node metastases with contrast effect. (B) Paraaortic lymph node metastases disappeared following 6 courses of chemotherapy.
Figure 4.
Figure 4.
Operative specimen and histological profile of the primary tumor. (A) Primary lesion has almost disappeared following 6 courses of chemotherapy. (B) Low power view of section from operative specimen, showing the absence of tumor cells and the presence of fibrous tissue with the partially collected foamy histiocytes. (Hematoxylin and eosin staining; original magnification, ×40). (C) Higher magnification from the fibrotic area showing fibroblasts laying down collagen and a scattering of inflammatory cells (Hematoxylin and eosin staining; original magnification, ×100).
See this image and copyright information in PMC

References

    1. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22:229–237. doi: 10.1200/JCO.2004.05.113. - DOI - PubMed
    1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691. - DOI - PubMed
    1. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26:2013–2019. doi: 10.1200/JCO.2007.14.9930. - DOI - PubMed
    1. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–1820. doi: 10.1001/jama.2010.1535. - DOI - PubMed
    1. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–2019. doi: 10.1200/JCO.2010.33.5091. - DOI - PubMed